Zoll Defibrillator Sales Growth, Upcoming Public AED Entry Buoy Stock In July
This article was originally published in The Gray Sheet
Executive Summary
Zoll Medical's upcoming entry into the public access automated external defibrillator (AED) market, coupled with revived sales growth in its third fiscal quarter, helped the firm's stock jump ahead 33% in July. The issue closed at $36.45, up $9 for the month.
You may also be interested in...
PMR Adverse Events, Elusive Efficacy Endpoints Cited In Panel Rejection
The reliance on hospitalization for angina as a safety endpoint in the clinical trials of CardioGenesis' Eclipse PMR (percutaneous myocardial revascularization) device masked the rate of significant adverse events related to the procedure, according to FDA's Circulatory System Devices Panel.
Zoll Banking On M-Series Superiority Claim In Entering Public AED Market
Zoll Medical is expecting the smaller size of its biphasic M-Series automated external defibrillator (AED) combined with FDA-cleared superiority claims over competing devices to result in a sizable chunk of the public access defibrillator market.
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.